PENDING Sample Clauses

PENDING. The Annexes and the acts referred to therein as adapted for the purposes of this Agreement as well as the Protocols shall form an integral part of this Agreement.

PENDING. An employee with a pending status are those employees who have provided a specimen sample but the final results have not been received from the laboratory and/or MRO to determine if the employee is negative or positive. Employees with a pending status are not eligible for referral by the Local Union until a final disposition has been received on their previous test.

PENDING. TITLE COUNTRY APPLICATION /PATENT ▇▇▇▇▇▇▇ REFERENCE STATUS NUMBER NUMBER DENDREON'S REFERENCE NUMBER ------------------------------------------------------------------------------------------------------------------------------------ Activation by Antigen-Pulsed Dendritic Cells ------------------------------------------------------------------------------------------------------------------------------------ Methods for In Vitro T Cell Japan Japanese Patent Application No. 7636-0030.42 Pending. Activation by Antigen Pulsed 08-502392 3005 Dendritic Cells ------------------------------------------------------------------------------------------------------------------------------------ Methods for In Vitro T Cell Europe European Application No. 7636-0030.45 Pending.

PENDING. “Article Having An Embedded Accessible Storage Member, Apparatus And Method For Using Same.” Filed 9/12/2008.

PENDING. Except as set forth on Disclosure Schedule 2.8, neither Somerset, its Subsidiaries, nor any of their respective employees, officers, members or directors (including the Stockholders) is the subject of any disciplinary proceedings before, or under investigation by, the NASD, the Securities and Exchange Commission ("SEC"), any securities exchanges or markets, any state securities division or other regulatory bodies. Except as disclosed on Disclosure Schedule 2.8, neither Somerset nor any of its Subsidiaries have received, since their inception to the date hereof, any written complaints or requests for refunds of commissions or other amounts paid. Annexed hereto as Disclosure Schedule 2.8 is a true and complete list of the Forms U-4 for all registered representatives and principals of Somerset or its Subsidiaries; all Forms BD and amendments thereto filed with the SEC by Somerset or its Subsidiaries; and Form ADV filed in order for Somerset Investment to become a registered investment advisor. Somerset has provided a BLLE with a true and complete copy of each of the forms listed on Disclosure Schedule 2.8. All such filings were, to the best knowledge of Somerset and the Stockholders, true and accurate in all material respects when filed and no further amendment thereof is currently required.

PENDING. 50 (*8) USA 615,400 14.3.96

PENDING. Final Order of Condemnation filed by SANDAG. San Diego Superior Court Case No. 37-2017-00005568-CU-EI-CTL SAN DIEGO ASSOCIATION OF GOVERNMENTS Plaintiff 2/14/2017 San Diego Association of Governments vs ▇▇▇ ▇▇▇▇▇, Toys “R” Us (aka Floit II) Civil - Unlimited Eminent domain/ Inverse condemnation PENDING. Proposed Order (re Motion for Possession) received, but not filed, by SANDAG. Motion Hearing scheduled for 08/04/2017. OTHER CASES San Diego Superior Court Case No. 37-2011-00101593-CU-TT-CTL / California Supreme Court Case No. S223603 SAN DIEGO ASSOCIATION OF GOVERNMENTS Respondent 1/6/2015 Cleveland National Forest Foundation, et al. vs San Diego Association of Governments Civil Appeal from CEQA Writ Argued and submitted for decision before California Supreme Court San Diego Superior Court Case No. 37-2015-00011360-CU-OR- CTL SAN DIEGO ASSOCIATION OF GOVERNMENTS Defendant/ Cross - Complainant 4/3/2015 Caryon Properties LLC vs San Diego Association of Governments

PENDING. Method 8-508985 August 31, 1995 1004 ----------------------------------------------------------------------------------------------------------------------------- Cell Separation Apparatus and Australia Australian Patent No. 700743 7636-0001.43 Issued 4/29/99. Method ----------------------------------------------------------------------------------------------------------------------------- Cell Separation Apparatus and Europe European Patent No. 778944 7636-0001.45 Issued 11/3/99. Method ----------------------------------------------------------------------------------------------------------------------------- Cell Separation Apparatus and New New Zealand Patent No. 292756 7636-0001.50 Issued 2/11/1999. Method Zealand ----------------------------------------------------------------------------------------------------------------------------- Reagent for Cell Separation U.S. U.S. Patent No. 4,927,749 7636-0002 Issued 5/22/1990. ----------------------------------------------------------------------------------------------------------------------------- Reagent for Cell Separation Canada Canadian Patent No. 1338492 7636-0002.40 Issued 7/30/1996. ----------------------------------------------------------------------------------------------------------------------------- Reagent for Cell Separation Japan Japanese Patent ▇▇▇▇▇▇▇ 7636-0002.42 Issued 4/18/1997. 1102 ----------------------------------------------------------------------------------------------------------------------------- Cell Separation Process U.S. U.S. Patent No. 4,927,750 7636-0003 Issued 5/22/1990. ----------------------------------------------------------------------------------------------------------------------------- Centrifugation Syringe, System U.S. U.S. Patent No. 5,577,513 7636-0004 Issued 11/26/1996. and Method ----------------------------------------------------------------------------------------------------------------------------- Centrifugation Syringe, System Australia Australian Patent No. 680383 7636-0004.43 Issued 11/13/1997. and Method -----------------------------------------------------------------------------------------------------------------------------

PENDING. There are no proceedings pending or, to the knowledge of the Company threatened, against or affecting the Company, any of its General Partners, its Parent or any Subsidiary in any court or before any governmental authority or arbitration board or tribunal which would reasonably be expected to have a Material Adverse Effect. Neither the Company nor any Subsidiary is in default with respect to any order of any court or governmental authority or arbitration board or tribunal which would reasonably be expected to have a Material Adverse Effect.